AKARI THERAPEUTICS PLC-ADR (AKTX) Fundamental Analysis & Valuation

NASDAQ:AKTX • US00972G2075

0.2512 USD
+0 (+1.87%)
At close: Mar 6, 2026
0.249 USD
0 (-0.88%)
After Hours: 3/6/2026, 8:00:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AKTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Overall AKTX gets a fundamental rating of 1 out of 10. We evaluated AKTX against 520 industry peers in the Biotechnology industry. AKTX may be in some trouble as it scores bad on both profitability and health. AKTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. AKTX Profitability Analysis

1.1 Basic Checks

  • AKTX had negative earnings in the past year.
  • In the past year AKTX has reported a negative cash flow from operations.
  • AKTX had negative earnings in each of the past 5 years.
  • AKTX had a negative operating cash flow in each of the past 5 years.
AKTX Yearly Net Income VS EBIT VS OCF VS FCFAKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -34.76%, AKTX is in the better half of the industry, outperforming 61.73% of the companies in the same industry.
  • AKTX's Return On Equity of -69.52% is in line compared to the rest of the industry. AKTX outperforms 55.19% of its industry peers.
Industry RankSector Rank
ROA -34.76%
ROE -69.52%
ROIC N/A
ROA(3y)-132.43%
ROA(5y)-132.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKTX Yearly ROA, ROE, ROICAKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AKTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKTX Yearly Profit, Operating, Gross MarginsAKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. AKTX Health Analysis

2.1 Basic Checks

  • AKTX has a worse debt/assets ratio than last year.
AKTX Yearly Shares OutstandingAKTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
AKTX Yearly Total Debt VS Total AssetsAKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -7.45, we must say that AKTX is in the distress zone and has some risk of bankruptcy.
  • AKTX's Altman-Z score of -7.45 is on the low side compared to the rest of the industry. AKTX is outperformed by 66.73% of its industry peers.
  • AKTX has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.09, AKTX is doing worse than 61.92% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -7.45
ROIC/WACCN/A
WACCN/A
AKTX Yearly LT Debt VS Equity VS FCFAKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.19 indicates that AKTX may have some problems paying its short term obligations.
  • AKTX has a Current ratio of 0.19. This is amonst the worse of the industry: AKTX underperforms 93.27% of its industry peers.
  • A Quick Ratio of 0.19 indicates that AKTX may have some problems paying its short term obligations.
  • AKTX has a worse Quick ratio (0.19) than 93.27% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
AKTX Yearly Current Assets VS Current LiabilitesAKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AKTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 84.21% over the past year.
EPS 1Y (TTM)84.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 24.98% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95%
EPS Next 2Y39.91%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKTX Yearly Revenue VS EstimatesAKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 50M 100M 150M
AKTX Yearly EPS VS EstimatesAKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

1

4. AKTX Valuation Analysis

4.1 Price/Earnings Ratio

  • AKTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKTX Price Earnings VS Forward Price EarningsAKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKTX Per share dataAKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AKTX's earnings are expected to grow with 24.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.91%
EPS Next 3Y24.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AKTX Dividend Analysis

5.1 Amount

  • AKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AKTX Fundamentals: All Metrics, Ratios and Statistics

AKARI THERAPEUTICS PLC-ADR

NASDAQ:AKTX (3/6/2026, 8:00:22 PM)

After market: 0.249 0 (-0.88%)

0.2512

+0 (+1.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)04-13
Inst Owners2.69%
Inst Owner Change278.78%
Ins Owners24.57%
Ins Owner Change0%
Market Cap8.98M
Revenue(TTM)N/A
Net Income(TTM)-15.77M
Analysts84
Price Target2.96 (1078.34%)
Short Float %92.63%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100%
Min EPS beat(2)100%
Max EPS beat(2)100%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-20.55%
PT rev (3m)-36.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)37.5%
EPS NY rev (1m)16.05%
EPS NY rev (3m)45.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS0.63
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.76%
ROE -69.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-132.43%
ROA(5y)-132.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -7.45
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y95%
EPS Next 2Y39.91%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.61%
OCF growth 3YN/A
OCF growth 5YN/A

AKARI THERAPEUTICS PLC-ADR / AKTX FAQ

What is the ChartMill fundamental rating of AKARI THERAPEUTICS PLC-ADR (AKTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to AKTX.


Can you provide the valuation status for AKARI THERAPEUTICS PLC-ADR?

ChartMill assigns a valuation rating of 1 / 10 to AKARI THERAPEUTICS PLC-ADR (AKTX). This can be considered as Overvalued.


What is the profitability of AKTX stock?

AKARI THERAPEUTICS PLC-ADR (AKTX) has a profitability rating of 1 / 10.


Can you provide the financial health for AKTX stock?

The financial health rating of AKARI THERAPEUTICS PLC-ADR (AKTX) is 0 / 10.